>Multi-pass Transmembrane Proteins Platform
The VLP (Virus like particles) technology platform based on the HEK293 expression system is specially set up by ACROBiosystems to express TPs on the host cell surface. The viral envelop/capsid protein then turns these cell surfaces into soluble lipid bilayer particles with highly-concentrated proteins amenable for antibody immunization and screening. The membrane protein-VLP complex displays correctly folded multi-pass TPs in its cell membrane induce and screen functional antibodies that recognize the natural conformation of the target.In addition to providing VLP based multi-pass TPs in our catalog, ACRO provides customized services as well.
The transmembrane region of multi-pass TPs is highly hydrophobic, and it is difficult to maintain the correct conformation in ordinary buffers once extracted from cell membrane. This problem can be solved by addition of detergents. ACROBiosystems has set up a complete platform for insect cell and mammalian cell expression, purification, and stabilization for difficult drug target TPs. ACRO performs detergent screening including DDM/CHS (Cat. No. DC-11) to increase solubility and ensure native fold of this protein in vitro.
"Nanodisc" is a synthetic phospholipid bilayer membrane structure composed of membrane scaffold proteins (MSPs) and phospholipid molecules. TP can be integrated into the special structure of Nanodisc after removal of the detergent so as to maintains its native folding, retain its biological activity and exhibitimproved hydrophilicity for a wide range of applications. For example, the detergent free formulation of Nanodisc based TP is compatible in CAR expression tests. ACROBiosystems has licensed the Nanodisc technology from University of Illinois and performed continuous optimization and improvement of the assembly process to make it suitable for industrial scale-up production. ACRO’s efforts have ensured a long-term stable supply of Nanodisc based TP products for the biopharma industry.
|Claudin18.2||CL2-H5547||Human Claudin18.2 Full Length Protein-VLP (HEK293)||Immunization|
|GPRC5D||GPD-H52P5||Human GPRC5D Full Length Protein-VLP (HEK293)|
|CCR5||CC5-H52P3||Human CCR5 Full Length Protein-VLP (HEK293)|
|CCR8||CC8-H52P4||Human CCR8 Full Length Protein-VLP (HEK293)|
|CD20||CDP-H52P6||Human CD20 Full Length Protein-VLP (HEK293)|
|VLP||VLP-H52C5||Virus-Like Particle (VLP) isotype control||Isotype Control|
|CD20||CD0-H52H3||Human CD20 / MS4A1 Full Length Protein, His Tag (HEK293) (SPR verified)||Immunization|
|CD20||CD0-H82E5||Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (HEK293)|
|CD20||CD0-C52H8||Cynomolgus CD20 / MS4A1 Full Length Protein, His Tag|
|Claudin18.2||CL2-H5546||Human Claudin-18.2 Protein, His Tag (active membrane protein)|
|Claudin18.2||CL2-H82E3||Biotinylated Human Claudin-18.2 Protein, His,Avitag™(active membrane protein)|
|CD133||CD3-H52H4||Human CD133 Protein, His Tag|
|CCR5||CC5-H52D1||Human CCR5 Protein, Flag,His Tag|
|GPRC5D||GPD-H52D3||Human GPRC5D Protein, Flag,His Tag|
|Buffer||DC-11||200x DDM CHS buffer||Maintain solubilization and activity of membrane proteins|
Dilute membrane proteins or antibodies
Prepare running buffer in SPR or BLI assay, etc.
|CD20||CD0-H52H1||Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)||Immunization|
|CD20||CD0-H82E3||Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc) (HEK293)|
|CD133||CD3-H52H1||Human CD133 Full Length Protein, His Tag (Nanodisc)|
|CD133||CD3-H82E6||Biotinylated Human CD133 Protein, His Tag (Nanodisc)|
|GPRC5D||GPD-H52D4||Human GPRC5D Protein, Flag,His Tag (Nanodisc)|
|MSP1D1||APO-H51H3||Human MSP1D1 Protein, His Tag (Nanodisc)||Isotype Control|
|MSP1D1||APO-H81Q5||Biotinylated Human MSP1D1 Protein, His,Avitag™ (Nanodisc)||Isotype Control|
The following SPR protocols are available for free.
Immobilized Human Claudin-18.2 Full Length Protein-VLP (Cat. No. CL2-H5547) at 5 μg/mL (100 μL/well) can bind Monoclonal Anti-Chimeric Claudin-18.2 Antibody, Human IgG1 with a linear range of 0.8-3 ng/mL (QC tested).
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (SPR verified) (Cat. No. CD0-H52H3) with a linear range of 0.4-3 ng/mL (in presence of DDM and CHS).
Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (HEK293) (Cat. No. CD0-H82E5) with a linear range of 4-63 ng/mL (in presence of DDM and CHS).
Biotinylated Human CD20, His,Avitag (HEK293) (Cat. No. CD0-H82E5) captured on Biotin CAP-Series S Sensor Chip can bind Rituximab with an affinity constant of 1.73 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200).
Human CD133 Full Length, His Tag (Nanodisc) （(Cat. No. CD3-H52H1)）on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human CD133 Full Length, His Tag (Nanodisc) (Cat. No. CD3-H52H1) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD133 (133-3) Antibody, Human IgG1 with a linear range of 0.2-4 ng/mL (QC tested).
Authors: Lionel Rougé et al.
Authors: Paige M. Glumac , Aaron M. LeBeau.
Journal: Glumac and LeBeau Clin Trans Med
Authors: Kenji Maeda, Debananda Das et al.
Journal: Journal of Biological Chemistry
Authors: Line Barington, Pia C. Rummel, et al.
Journal: Journal of Biological Chemistry
This web search service is supported by Google Inc.